{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"1.8","upperLimit":"4.6","value":"3.2"},{"groupId":"OG002","lowerLimit":"2.1","upperLimit":"2.1","value":"2.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Time to best response will be defined as the time from initiation of ruxolitinib treatment to the time of best objective status assessment of response.","dispersionType":"Full Range","groups":[{"description":"Cohort 1) 5mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"OG000","title":"Phase I 5 mg Ruxolitinib"},{"description":"Cohort 2) 10mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"OG001","title":"Phase I 10 mg Ruxolitinib"},{"description":"Cohort 3) 15mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"OG002","title":"Phase I 15 mg Ruxolitinib"}],"paramType":"MEDIAN","populationDescription":"Time to best response calculated only for participants who achieved a PR or better.","reportingStatus":"POSTED","timeFrame":"Approximately 180 days after treatment start (disease assessment occurred after every 28-day cycle)","title":"Time to Best Response","type":"SECONDARY","unitOfMeasure":"months"}